撤市药物的遗传药理学  

Mechanism of pharmacogenetics on drug withdrawal

作　　者：陈旺青[1] 张伟[1] 

机构地区：[1]中南大学临床药理研究所

出　　处：《中国临床药理学与治疗学》2011年第9期1065-1071,共7页Chinese Journal of Clinical Pharmacology and Therapeutics

基　　金：国家自然科学基金资助项目(200830801421);国家科技重大专项"重大新药创制"(2009ZX09501-032)

摘　　要：药物安全性、药动学和药效学是决定候选化合物能否成药的重要指标,而上市后的药物遭遇撤市则多因发生严重的药物不良反应所致。药物在不同个体/人群中可能产生不同的药动学和药效学效应,甚至表现为不良反应,遗传药理学重在研究机体遗传因素对二者的影响。阐明遗传变异导致的药物药理作用异常的机制,不仅能加强药物使用的安全性,更全面地描述药物的适应范围,也可能改写药物被淘汰的命运,使之更好地服务于人类。Drug safety,pharmacokinetics and pharmacodynamics are the most important indicators that determine whether the candidate compounds can can be developed into drugs.The listed drugs withdrawn from the market were often of serious adverse drugs reactions.Drugs in different individuals/groups may have different pharmacokinetics and pharmacodynamics,and even cause adverse drug reactions（ADR）.While pharmacogenetics focuses on the influence of genetic factors on both.To clarify the mechanism of abnormal reactions caused by genetic variations,not only enhance drugs safety,with a more comprehensive description of the indications,but also could rewrite the fate of drugs to be withdrawn,which can make it better service to humanity.

关 键 词：遗传药理学 药物撤市 遗传因素 多态 药物不良反应 

分 类 号：R97[医药卫生—药品]